We are live on ! Find out more
SCPH

scPharmaceuticals

Delisted

SCPH was delisted on the 6th of October, 2025.

95 hedge funds and large institutions have $170M invested in scPharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

368% more call options, than puts

Call options by funds: $721K | Put options by funds: $154K

300% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 6

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

62% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 21

40% more capital invested

Capital invested by funds: $121M → $170M (+$48.8M)

23% more funds holding

Funds holding: 7795 (+18)

2.69% less ownership

Funds ownership: 77.16%74.46% (-2.7%)

Holders
95
Holders Change
+18
Holders Change %
+23.38%
% of All Funds
1.36%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
24
Increased
34
Reduced
21
Closed
6
Calls
$721K
Puts
$154K
Net Calls
+$567K
Net Calls Change
+$205K

SCPH Hedge Fund Activity: Q3 2024 in Review

95 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q3 2024, worth a combined $170M — up 40% from $121M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SCPH positions and 6 closed out — a net gain of 18 holders — while 34 added to existing stakes and 21 trimmed.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $9.91M. The largest seller was Bank of Montreal, exiting entirely with an estimated $1.54M sold.

  • 95 institutional investors held scPharmaceuticals (SCPH) as of Q3 2024, up from 77 in Q2 2024.
  • Funds reported $170M of scPharmaceuticals stock for Q3 2024, up 40% quarter-over-quarter.
  • 24 funds opened new scPharmaceuticals positions in Q3 2024 and 6 closed out, a net change of +18 holders.
  • The largest scPharmaceuticals buyer in Q3 2024 was Suvretta Capital Management, an estimated $9.91M added.
  • The largest scPharmaceuticals seller in Q3 2024 was Bank of Montreal, an estimated $1.54M sold.

Based on aggregated 13F filings for Q3 2024.